Abstract
Ninety-nine patients with advanced breast cancer were randomized to receive either cyclophosphamide continuously or a combination of cyclophosphamide, methotrexate, 5-fluorouracil and vinblastine given intermittently. The number and duration of objective responses were greater in patients receiving the combination but the differences between the two treatments did not achieve formal significance. The combination was logistically easier to manage and produced less toxicity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Rubens, R., Knight, R. & Hayward, J. Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 32, 730–736 (1975). https://doi.org/10.1038/bjc.1975.284
Issue Date:
DOI: https://doi.org/10.1038/bjc.1975.284
This article is cited by
-
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
British Journal of Cancer (2002)
-
Chemotherapy of breast cancer
Medical Oncology and Tumor Pharmacotherapy (1984)
-
Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?
Breast Cancer Research and Treatment (1983)
